A randomized, multi-center pragmatic trial evaluating omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving Paclitaxel portion of dose-dense Adriamycin-Cyclophosphamide (AC) and Paclitaxel (neo) adjuvant chemotherapy – when less is more